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Abstract
Objective: People who are severely obese due to melanocortin‐4 receptor (MC4R)
deficiency experience hyperphagia and impaired fullness after a meal (satiety). Meal‐
induced satiety is influenced by hormones, such as peptide‐YY (PYY), which are
released by enteroendocrine cells upon nutrient delivery to the small intestine.
Design: We investigated whether gastric emptying and PYY levels are altered in
MC4R deficiency.
Methods: Gastric emptying was measured with a gastric scintigraphy protocol using
technetium‐99m (99Tcm)‐Tin Colloid for 3.5 h in individuals with loss of function
MC4R variants and a control group of similar age and weight. In a separate study, we
measured plasma PYY levels before and at multiple time points after three stan-
dardised meals given to individuals with MC4R deficiency and controls. Fasting PYY
(basal secretion) and postprandial PYY levels were measured and the area under the
curve and inter‐meal peak were calculated.
Results: We found that gastric emptying time was significantly delayed and per-
centage meal retention increased in individuals with MC4R deficiency compared to
obese controls. In addition, fasting and mean PYY secretion throughout the day were
decreased in MC4R deficiency, whereas postprandial PYY secretion was unaltered.
Conclusion: Delayed gastric emptying and reduced basal PYY secretion may con-
tribute to impaired satiety in people with obesity due to MC4R deficiency.
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1 | INTRODUCTION
Melanocortin‐4 receptor (MC4R) signalling plays a pivotal role in the
regulation of body weight and genetic disruption of MC4R causes
hyperphagia and severe obesity in mice and humans.1,2 Heterozygous
loss of function mutations in MC4R represent the commonest
monogenic form of obesity and are found in 2%–5% of severely
obese children and adults in multiple populations.2,3 The effects of
MC4R signalling on hunger and the drive to eat are predominantly
mediated by neuronal circuits in the hypothalamus, where stimulation
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of MC4R expressing neurons by the endogenous agonist
α‐melanocyte‐stimulating hormone (α‐MSH) leads to a reduction in
food intake in the fed state.4 MC4R is also highly expressed in the
dorsal motor nucleus of the vagus (DMV), the site of preganglionic
parasympathetic vagal efferent neurons that innervate the gastro-
intestinal system and in the nucleus tractus solitarius (NTS) and no-
dose ganglion, sites that receive vagal afferents from the stomach
and duodenum.5 Administration of melanocortin agonists into the
NTS or DMV inhibits food intake and decreases phasic gastric con-
tractions, suggesting a role in gastric motility and meal‐induced sa-
tiety.5,6 Interestingly, a large study of people carrying a common
noncoding obesity‐associated genetic variant that lies downstream of
MC4R (rs17782313) found that this variant was associated with de-
layed gastric emptying.7
MC4R is also expressed in enteroendocrine cells8; a subset of
these cells release peptide‐YY (PYY) in response to nutrient delivery
to the small intestine. Infusion and functional imaging studies have
shown that PYY administration to healthy volunteers leads to satiety
by activating brainstem neural circuits.9–11 Here, we studied in-
dividuals with heterozygous loss of function mutations in MC4R and
a control group of similar age and weight. We first used technetium‐
labelled gastric scintigraphy,12 which relies on the labelling of foods
to measure both the solid and liquid phases of gastric emptying. In a
second study, we studied basal and postprandial PYY in people with
loss of function mutations in MC4R and obese controls.
2 | METHODS
2.1 | Participants
All studies were approved by the Cambridge Local Research Ethics
Committee and each subject provided written informed consent.
People with MC4R mutations were identified by Sanger sequencing
of all participants in the Genetics of Obesity Study (GOOS), a cohort
of >7000 individuals with severe early‐onset obesity defined as a
body mass index (BMI; weight in kilograms divided by the square of
the height in metres) standard deviation score greater than 3; onset
less than 10 years.2,13 None of the participants were taking anti-
obesity medication or dietary treatment for weight loss. Data were
compared with controls of same sex and similar age and BMI with a
normal MC4R genotype recruited through public advertisement.
Details on participants in the gastric emptying study are provided
in Table 1 and for the PYY secretion study in Table 2. Pregnant and
breastfeeding women were excluded from the study. The studies
were conducted at the Wellcome‐MRC Institute of Metabolic
Science Translational Research Facility and the Nuclear Medicine
Department, Addenbrooke's Hospital, Cambridge.
TABLE 1 Baseline characteristics of
study participants in the gastric emptying
study
MC4R Variant
Sex Age (years) BMI (kg/m2)
Fasting glucose
(mmol/l)
MC4R Control MC4R Control MC4R Control MC4R Control
I125K (het) M M 27.5 25.6 47.1 43.8 4.5 5.9
C271Y (het) F F 20.2 33.6 52.1 55.4 5.3 5.4
Y35X; D37V (het) F F 31.2 20.8 32.7 33.6 4.8 4.8
A68V (het) M M 51.2 38.9 27.1 29.4 4.8 5.8
C271Y (het) F F 24.3 30.4 38.4 38.4 4.1 4.3
D122Y (het) M M 41.2 40.9 39.5 36.3 4.9 5.4
L211MfsX6;
P299H (het)
M M 34.9 35.0 24.2 28.6 4.8 5
R165Q M M 45.2 40.0 22.6 23.9 4.2 4.8
Q115EfsX7 M M 33.6 36.4 40.1 38.3 4.5 3.8
Abbreviation: BMI, body mass index; MC4R, melanocortin 4 receptor.
TABLE 2 MC4R‐deficient participants and obese controls in the
postprandial PYY study
MC4R variant Age (years) BMI (kg/m2)
F280AfsX12 (het) 40.6 41.3
T112NfsX11 (het) 25.4 43.3
T112NfsX11 (het) 20 67.3
C271Y (het) 39.8 44.3
C271Y (het) 42.7 41
I125K (het) 21.5 32
Obese control 37.9 44.1
Obese control 65.2 35.8
Obese control 71.8 43.5
Obese control 42.0 40.9
Obese control 59.4 38.5
Abbreviation: PYY, peptide‐YY; MC4R, melanocortin 4 receptor.
2 | SEELIG ET AL.
2.2 | Study design gastric emptying study
Study participants for this study were not taking opiates, prokinetics,
anticholinergics or any medication affecting the central nervous
system or gastrointestinal motility; they did not have disorders
affecting the gastrointestinal tract. A wide variety of radionuclide
markers have been used to follow gastric emptying. Solid‐phase
radionuclide markers must have a high labelling efficiency, and
the radiolabel must not elute from the food material during the
procedure. The most frequently used solid‐phase marker is labelled
eggs. In this study, 11 MBq 99Tcm‐Tin Colloid was added to two egg
whites, according to standardised criteria.12 Oral 99Tcm‐Tin Colloid is
a nonabsorbable tracer with very low tissue radiation exposure.14 The
eggs were allowed to incubate for 5min then scrambled and cooked in
a pan until firm. After a 6‐h fasting period, all participants consumed a
standardised meal consisting of 120 g scrambled egg white, two slices
of toasted white bread, 30 g jam and 120ml water, as the stomach
needs a working volume of food to demonstrate normal emptying
processes. Participants were asked to consume the radio‐labelled meal
within 10min before the first anterior and posterior images were
obtained with a gamma camera (GE Discovery 630). Then images were
taken at 15‐min intervals during the first 2 h and at 30‐min intervals for
the next 1.5 h. The study was completed 3.5 h after the consumption of
the radio‐labelled meal. For the analysis, regions of interest were drawn
and geometric means of decay‐corrected counts were determined at
each time point to estimate the proportion of 99m‐Tc from the
stomach. All gastric emptying data were analysed by two investigators
blinded to genotype. Several fits were tested: the mono‐exponential
fit was necessary and sufficient to provide an optimal R2. The
bi‐exponential fit did not improve the quality of the fit. Times, when
10%, 50% (t1/2), and 90% of the meal was emptied, were determined
for each participant. Discrete variables are expressed as the percentage
of the initial counts remaining in a region of interest (ROI) drawn
around the stomach and continuous variables as median (interquartile
range [IQR]). Raw counts (median and interquartile range) are provided
in Table 3.
2.3 | Study design gut hormone study
All subjects in this study had normal levels of lipids, glucose and
thyroid hormones. None of the participants had been diagnosed with
diabetes mellitus or gastrointestinal disease, and subjects were not
taking any medications. In addition, obese controls had a normal
MC4R genotype and no history suggestive of other known mono-
genic obesity syndromes. PYY concentrations were obtained during a
12‐h sampling period with three meals standardised for macro-
nutrient and caloric content after a 10‐h overnight fast. Meals were
provided at 8 a.m., noon, and 5:30 p.m. Blood was drawn every half
hour from 7:30 a.m. to 8:30 p.m. Meals were calculated to provide
20%, 35% and 35% of daily individual energy requirements
(breakfast, lunch and dinner, respectively) using the Schofield
formula.15 The macronutrient content of the meals was 20% protein,
30% fat and 50% carbohydrates and energy content ranged from 400
to 600 Calories. Visual analogue scales (VAS), which require re-
spondents to specify their level of hunger or fullness by indicating a
position along a continuous line between two end‐points (not hungry,
most hungry you have ever been; not full, most full you have ever
been), were used to assess hunger and fullness every 30min starting
from 07:30 h. Blood for the measurement of PYY levels was collected
from an indwelling intravenous catheter in EDTA heparin tubes.
Blood was spun immediately at 4°C, and plasma was frozen and
stored at −80°C until analysis. Plasma PYY levels were measured
using an established in‐house radioimmunoassay (RIA) described
previously.11 The detection limit was 2.5 pmol/L with an intra‐assay
coefficient variation of 5.8%. As some indwelling cannulas failed, we
have PYY measurements up to 7:00 PM for all participants and these
were included in the analysis.
2.4 | Statistical analysis
The Fisher's exact test was used for categorical data and unpaired t
tests or the Mann–Whitney U test for continuous data to compare
changes across groups. p‐ < .05 was defined as significant. Data were
analysed using GraphPad Prism Version 7 (GraphPad Software Inc).
3 | RESULTS
3.1 | Gastric emptying
Nine people carrying a mutation in MC4R (cases) and nine controls
were included in this study (Table 1). Cases and controls were
TABLE 3 Raw counts (median, interquartile range [IQR]) for all
time points
Time points
Raw counts (median, IQR)
MC4R Controls
T1 8061 (6770−12838) 7842 (6432−12117)
T2 7526 (5579−11291) 6701 (6313−11959)
T3 6832 (4655−10391) 7235 (4580−9517)
T4 6207 (3403−8547) 5607 (3652−7906)
T5 5514 (2647−7137) 4297 (3035−7070)
T6 4719 (1973−6543) 3195 (2383−5864)
T7 4422 (1635−5935) 2829 (2001−4363)
T8 3730 (1256−5242) 2318 (1529−3407)
T9 3474 (1065−4643) 1833 (1144−2600)
T10 2240 (734–3347) 908 (569–1683)
T11 1509 (332–2344) 243 (175–1010)
T12 1045 (197–1497) 170 (121–423)
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comparable in age (MC4R: 33.6 [25.9–43.2] years; controls: 35.0
[28.0–39.5]), BMI (MC4R: 38.4 [25.7–43.6] kg/m2; controls: 36.3
[29.0–41.1] kg/m2) and sex (66.6% males in both groups). Fasting
glucose levels were comparable in both groups (MC4R: 4.8 [4.4–4.9]
mmol/l; controls: 5.0 [4.6–5.6] mmol/l).
We found that after consuming a meal of identical volume, 10%
emptying time was significantly delayed in people with MC4R defi-
ciency compared with controls (MC4R: 9.3 (6.2–11.4) min; controls:
5.6 (4.9–7.0) min; p = .03). Similarly, 50% emptying time was delayed
in people with MC4R deficiency (MC4R: 61.2 (40.7–74.9) min; con-
trols: 36.8 (32.4–45.8) min; p = .03) and 90% emptying time was
significantly longer in people with MC4R deficiency compared to
controls (MC4R: 203.2 (135.3–248.9) min; controls: 122.4
(107.7–152.1) min; p = .03) (Figure 1). Percentage retention at the
end of the test was 9.7% (3.4–15.3) in people with MC4R deficiency
compared to 2.1% (1.3–4.6) in controls (p = .02).
3.2 | Fasting and post‐prandial PYY secretion
Six people carrying a loss of function mutation in MC4R (cases) and
five controls were included in this study (Table 2). The mean age was
31.7 (20–43) years in people with MC4R deficiency and 55 (38–72) in
controls. Mean BMI was 44.9 (32.0–67.3) kg/m2 in people with
MC4R deficiency and 40.6 (35.8–44.1) kg/m2 in controls. Fasting
PYY levels were 47% lower in people with MC4R deficiency com-
pared to obese controls (9.0 ± 1.5 pmol/l vs. 16.9 ± 2.3 pmol/l, re-
spectively, [p = .015], Table 4). Average PYY concentrations were also
29% lower (Table 4). To assess postprandial PYY secretion (Figure 2),
several parameters were calculated: the average intermeal peak as
the combined maximum value between breakfast/lunch and lunch/
F IGURE 1 Gastric emptying in people with melanocortin 4
receptor (MC4R) deficiency and controls. (A) Illustrative scintigraphic
images of gastric emptying over 3.5 h in a representative participant
with a heterozygous loss of function mutation in MC4R and healthy
control. (B) Exponentially fitted gastric emptying time in people with
heterozygous loss of function mutations in MC4R and matched
controls. Time‐activity curve for food retention in the stomach is
normalised to the activity present at time zero when the whole meal
is contained within the stomach; time in minutes (min) (*p < .05)
[Color figure can be viewed at wileyonlinelibrary.com]
TABLE 4 PYY levels in individuals with MC4R deficiency and obese controls
Obese
controls (n = 5)
Individuals with MC4R
deficiency (n = 6) p value
Fasting PYY (pmol/l) 16.9 ± 2.3 9.0 ± 1.5 .015
Mean PYY (pmol/l) 21.4 ± 0.5 15.1 ± 0.6 .00002
Area under the curve 111.1 ± 44.6 149 ± 23.2 .447
Inter‐meal peak (pmol/l) 28.2 ± 12.6 20.2 ± 2.6 .217
Percentage change in PYY 30min after all
meals (%)
16.9 ± 8.3 18.6 ± 9.9 .900
Percentage change in PYY 60min after all
meals (%)
14.8 ± 8.9 18.2 ± 29.8 .922
VAS hunger scores (area under the curve) 82.2 ± 5.4 72.2 ± 6.4 .2744
VAS fullness scores (area under the
curve)
140.9 ± 5.4 137.3 ± 8.3 .7369
Abbreviations: PYY, peptide‐YY; MC4R, melanocortin 4 receptor; VAS, visual analogue scales.
4 | SEELIG ET AL.
dinner, the percentage change in PYY 30min and 60min after
breakfast, lunch and dinner combined and the area under the curve
(AUC) using the trapezoidal method with fasting PYY as a baseline
and allowing for positive and negative peaks. There was no difference
in 30 or 60min postprandial PYY secretion, AUC or in the intermeal
peak between individuals with MC4R variants (p = .900 for 30min,
p = .922 for 60min, p = .447 for AUC and p = .217 for intermeal peak).
VAS scores for hunger and fullness were not different between the
two groups throughout the study period (Table 4).
4 | DISCUSSION
Here, using the gold standard method, we found that gastric emp-
tying is delayed in people with heterozygous loss of function muta-
tions in MC4R. In addition, we show that people with loss of function
mutations in MC4R have lower basal PYY secretion. These findings
warrant replication in a larger cohort, accepting the challenges of
studying monogenic disorders.
Why might MC4R deficiency be associated with delayed gastric
emptying? The regulation of gastric emptying involves the co-
ordination of smooth muscle contraction driven by the enteric ner-
vous system and the autonomic nervous system. The regulation of
the gastrointestinal tract by the autonomic nervous system is com-
plex. Whereas, in general, sympathetic tone decreases secretions and
gastric motility; the parasympathetic nervous system has both in-
hibitory and excitatory effects on gastrointestinal tone and motility.16
Previous studies of heart rate variability in MC4R showed greater
parasympathetic activity and relatively lower sympathetic activity
than in healthy controls.17,18 In view of our findings, we suggest that
autonomic dysfunction in MC4R deficiency may contribute to im-
paired gastric motility. Gastroparesis, defined as delayed gastric
emptying in the absence of mechanical obstruction, is usually
associated with symptoms of nausea, vomiting, early satiety, and
bloating,19 as commonly seen in people with autonomic dysfunction
secondary to type 2 diabetes. However, the magnitude of the delay
to gastric emptying seen in MC4R deficiency is modest (10% gastric
retention at end of study) compared to that seen in people with
diabetic gastroparesis (30% gastric retention at 4 h) and thus would
not be expected to lead to marked gastrointestinal symptoms, in-
cluding bloating and prolonged fullness after a meal.20
Gastric emptying is the major determinant of the amount of ingested
nutrients that reach the small intestine, which, in turn, determines the
timing and amplitude of secretion of peptide‐YY (PYY), which is known to
promote satiety and inhibit gastric motility.8,11,21 In rodents, MC4Rs are
the second most abundant G‐protein coupled receptor on the cell
membrane of PYY and GLP‐1 expressing enteroendocrine L cells.8 We
found lower fasting and mean PYY levels throughout the day without a
change in peak postprandial PYY secretion. MC4R signalling may affect
basal PYY secretory tone but does not appear to influence the nutrient‐
stimulated postprandial increase in PYY, although we acknowledge that
these findings are preliminary and larger studies in normal weight, obese
and MC4R‐deficient people are needed. Infusion of PYY has been shown
to modulate brain regions involved in satiety in human functional MRI
studies,10 and therefore, a lower basal secretion could contribute to im-
paired satiety in MC4R deficiency. In future, it would be interesting to
measure GLP‐1 levels, which reflect secretion by proximal L‐cells rather
than distal L‐cells, which secrete PYY. Given the delay in gastric emptying
seen in people with MC4R deficiency, it is possible that for a lower
fraction of nutrient load delivered, there is a similar stimulation of PYY
release at 30 and 60min after food intake. Also reduced gastric emptying
rate in MC4R deficiency may reduce L‐cell number as the converse is true
in response to accelerated nutrient delivery to the small intestine after
Roux‐en‐Y bypass surgery.22
In conclusion, by studying people with MC4R deficiency, we
have shown that MC4R signalling modulates gastric emptying and
F IGURE 2 Peptide‐YY (PYY) levels in
relation to meals in people with melanocortin 4
receptor (MC4R) deficiency and controls. PYY
concentrations in five obese subjects (blue), and
six obese people with MC4R deficiency (red)
during an 11:30‐h sampling period with three
meals standardised for macronutrient and
caloric content. Meals were provided at 8 a.m.,
noon, and 5:30 p.m (arrows). Samples were
taken every 30min. Results are expressed as
mean ± SE [Color figure can be viewed at
wileyonlinelibrary.com]
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PYY secretion in humans. Understanding how melanocortin circuits in
the brain detect and respond to gut‐derived neural and hormonal
signals may provide further insights into the regulation of meal‐
induced satiety.
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